Janux Therapeutics, Inc. (JANX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $52.33M | -87.8% |
| 2024 | $430.61M | +2142.2% |
| 2023 | $19.20M | -62.7% |
| 2022 | $51.43M | +44.5% |
| 2021 | $35.58M | +355.4% |
| 2020 | $7.81M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $52.33M | -87.8% |
| 2024 | $430.61M | +2142.2% |
| 2023 | $19.20M | -62.7% |
| 2022 | $51.43M | +44.5% |
| 2021 | $35.58M | +355.4% |
| 2020 | $7.81M | — |